PepGen price target raised to $7 from $6 at Guggenheim

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on PepGen (PEPG) to $7 from $6 and keeps a Buy rating on the shares. The firm, which anticipates data from the FREEDOM2 5 mg/kg MAD cohort in March, cites its analysis of the FREEDOM2 outlook for increasing its price target noting that its base case scenario assumes SI correction in the high teens.